Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Hoeper, Marius M ^a   Behr, Juergen ^b   Held, Matthias ^c   Grunig, Ekkehard ^d   Vizza, C Dario ^e   Vonk Noordegraaf, Anton ^f   Lange, Tobias J ^g   Claussen, Martin ^h   Grohé, Christian ⁱ   Klose, Hans ^j   Olsson, Karen M ^a   Zelniker, Thomas ^k   Neurohr, Claus ^b   Distler, Oliver ^l   Wirtz, Hubert ^m   Opitz, Christian ⁿ   Huscher, Doerte ^o   Pittrow, David ^p   Gibbs, J Simon R ^q  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Medical Mission Hospital   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h LungenClinic   (Germany)

ⁱ Department of Respiratory Medicine   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m UNIVERSITY OF LEIPZIG   (Germany)

ⁿ German Red Cross Hospital   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p Technical University   (Germany)

^q NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; VASODILATOR AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OXYGEN SATURATION; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL RATE; TOTAL LUNG CAPACITY; AGED; CHRONIC DISEASE; COMPLICATION; HYPERTENSION, PULMONARY; LUNG FIBROSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REGISTER;

AGED; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC INTERSTITIAL PNEUMONIAS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; REGISTRIES; SURVIVAL RATE; VASODILATOR AGENTS;

EID: 84956660431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141911     Document Type: Article

References (27)

1. Travis WD, Costabel U, Hansell DM, King TE Jr., Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. doi: 10.1164/rccm.201308-1483ST PMID: 24032382.
2. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008; 31(6):1357-67. Epub 2008/06/03. 31/6/1357 [pii] doi: 10.1183/09031936.00171307 PMID: 18515559.
3. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl):D109-16. Epub 2013/12/21. doi: 10.1016/j.jacc.2013.10.036 PMID: 24355635.
4. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015; 46(1):186-96. Epub 2015/04/04. doi: 10.1183/09031936.00217614 PMID: 25837040; PubMed Central PMCID: PMC4486374.
5. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131(3):650-6. doi: 10.1378/chest.06-1466 PMID: 17317730.
6. Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008; 76(3):288-94. Epub 2008/01/25. doi: 10.1159/000114246 PMID: 18216461.
7. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007; 30(4):715-21. Epub 2007/07/13. doi: 10.1183/09031936.00107206 PMID: 17626111.
8. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med. 2012; 106(11):1613-21. Epub 2012/08/21. doi: 10.1016/j.rmed.2012.07.013 PMID: 22902266.
9. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration. 2013; 85(6):456-63. Epub 2012/12/22. doi: 10.1159/000345221 PMID: 23257350.
10. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3):746-52. Epub 2006/03/16. doi: 10.1378/chest.129.3.746 PMID: 16537877.
11. Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009; 136(1):10-5. Epub 2009/02/20. doi: 10.1378/chest.08-2306 PMID: 19225068.
12. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009; 64(10):883-8. Epub 2009/06/24. thx.2008.112847 [pii] doi: 10.1136/thx.2008.112847 PMID: 19546096.
13. Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest. 2013; 144(2):564-70. Epub 2013/03/02. doi: 10.1378/chest.12-2298 PMID: 23450321; PubMed Central PMCID: PMCPMC3734888.
14. Humbert M, Lau EM, Montani D, Jais X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014; 130(24):2189-208. doi: 10.1161/CIRCULATIONAHA.114.006974 PMID: 25602947.
15. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014; 190(2):208-17. Epub 2014/06/18. 10.1164/rccm.201403-0446OC. 24937643; PubMed Central PMCID: PMC4226056. doi: 10.1164/rccm.201403-0446OC PMID: 24937643
16. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363(7):620-8. Epub 2010/05/21. doi: 10.1056/NEJMoa1002110 PMID: 20484178.
17. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011; 154S1:S45-S53. Epub 2012/01/10. doi: 10.1016/s0167-5273(11)70492-2 PMID: 22221973.
18. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30(20):2493-537. Epub 2009/08/29. ehp297 [pii] doi: 10.1093/eurheartj/ehp297 PMID: 19713419.
19. Tanabe N, Taniguchi H, Tsujino I, Sakamaki F, Emoto N, Kimura H, et al. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology. 2015; 20(5):805-12. Epub 2015/04/02. doi: 10.1111/resp.12530 PMID: 25828844.
20. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013; 41(6):1292-301. doi: 10.1183/09031936.00079512 PMID: 23018917.
21. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2012; 39(4):945-55. Epub 2011/09/03. doi: 10.1183/09031936.00078411 PMID: 21885399.
22. Brewis MJ, Church AC, Johnson MK, Peacock AJ. Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. Eur Respir J. 2015. Epub 2015/08/22. doi: 10.1183/13993003.02307-2014 PMID: 26293503.
23. King TE Jr., Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177(1):75-81. Epub 2007/09/29. doi: 10.1164/rccm.200705-732OC PMID: 17901413.
24. King TE Jr., Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(1):92-9. Epub 2011/04/09. doi: 10.1164/rccm.201011-1874OC PMID: 21474646.
25. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010; 62(7):2101-8. Epub 2010/05/28. doi: 10.1002/art.27466 PMID: 20506355.
26. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158(9):641-9. Epub 2013/05/08. doi: 10.7326/0003-4819-158-9-201305070-00003 PMID: 23648946.
27. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013; 42(6):1622-32. Epub 2013/05/18. doi: 10.1183/09031936.00104612 PMID: 23682110.